Soleno Therapeutics Inc (SLNO)

In the past six months, Soleno Therapeutics' stock has been significantly impacted by an acquisition agreement. On April 6, 2026, Neurocrine Biosciences announced a definitive agreement to acquire Soleno Therapeutics for $53.00 per share in cash, valuing the transaction at approximately $2.9 billion, leading to a surge in the stock price. Prior to the acquisition news, Soleno Therapeutics reported earnings on February 25, 2026, after the market close for Q4 2025, beating both EPS and revenue expectations, but SLNO shares declined 7.1% the day following the earnings announcement. The stock price as of April 8, 2026, was $52.60, with a 52-week range between $29.43 and $90.32.

The demand for VYKAT XR, Soleno Therapeutics' primary product for treating Prader-Willi syndrome, is unlikely to exhibit significant seasonality. Treatments for chronic rare diseases typically have a relatively stable and ongoing demand once patients are diagnosed and begin therapy.

Soleno Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for rare diseases, particularly metabolic and neurobehavioral disorders. Their lead product, VYKAT XR (diazoxide choline extended-release tablets), received FDA approval on March 26, 2025, for treating hyperphagia in patients aged 4 years and older with Prader-Willi syndrome (PWS). The commercial launch of VYKAT XR began in April 2025, generating $66.0 million in Q3 2025 revenue with 764 active patients, and $190 million in total sales by the end of 2025 with approximately 1,250 patients initiating treatment.

Soleno Therapeutics, Inc. is headquartered in Redwood City, California, United States. The company's stock is listed on the NASDAQ Capital Market in the US, and also on the Deutsche Boerse AG and Borsa Italiana in Europe, indicating a presence in both the United States and European markets for its securities.

Soleno Therapeutics has cultivated a positive brand reputation, particularly within the rare disease community, driven by its focus on developing novel therapeutics for unmet medical needs. The FDA approval of VYKAT XR in March 2025 significantly bolstered its reputation as an innovator. Analyst sentiment towards Soleno Therapeutics has generally been positive, with a consensus recommendation of "Hold" from thirteen research firms as of April 10, 2026.

Soleno Therapeutics, Inc. has a significant institutional ownership base. As of April 8, 2026, there were 256 institutional owners and shareholders who had filed 13D/G or 13F forms with the SEC, holding a total of 64,343,096 shares. Institutional ownership accounts for 112.56% of the shares, while individuals hold 2.69%.